Agilent Technologies (A) stock is in focus after the company received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay, a companion diagnostic for several gastrointestinal cancers.

Against this FDA approval backdrop, Agilent Technologies’ share price of $137.89 sits after a 7 day share price return of 5.86% and a 90 day share price return of 20.04%. The 1 year total shareholder return of 16.28% points to momentum building over a longer horizon.

If this kind of cancer diagnostics story has your attention, it could be a good time to size up other healthcare focused opportunities through the 41 healthcare AI stocks

Bulls see Agilent Technologies riding FDA backed diagnostics momentum. Bears point to past five year shareholder returns that lag its three year record. Do the current valuation signals back the optimism or the caution?

Most Popular Narrative: 14.4% Undervalued

Agilent Technologies closed at $137.89 while the most followed narrative sets fair value at $161.00. That gap rests on a detailed earnings and margin story.

Strategic investments in higher-margin recurring revenue streams, including consumables, software, services, and digital platforms, are gaining traction, with CrossLab and services delivering consistent mid-single-digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.

It is worth asking what sits behind that confidence in future margins and earnings for Agilent Technologies. The narrative leans on specific revenue growth, profit trajectory, and a future earnings multiple that has to hold up through 2029. The key assumptions tie those pieces together in a way that is not obvious from the current share price chart.

Result: Fair Value of $161.00 (UNDERVALUED)

However, the Agilent Technologies story could look very different if tariff related costs remain elevated or if funding pressures in academia and government persist.

Next Steps

With sentiment around Agilent Technologies clearly split, it can be useful to walk through the numbers directly and stress test the story. To see what has investors optimistic about the company right now, take a closer look at the 3 key rewards

Looking for more investment ideas beyond Agilent Technologies?

If Agilent Technologies has you thinking bigger about your portfolio, now is a good time to review fresh ideas that could adjust your mix before the next move.

• Target potential mispricings by reviewing companies highlighted in the 51 high quality undervalued stocks.
• Strengthen your income stream by checking out stocks featured in the 8 dividend fortresses.
• Prioritise resilience by reviewing companies surfaced in the 84 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.